SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-295997
Filing Date
2020-11-17
Accepted
2020-11-17 16:05:54
Documents
13
Period of Report
2020-11-17
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d88033d8k.htm   iXBRL 8-K 28153
2 EX-4.1 d88033dex41.htm EX-4.1 549840
  Complete submission text file 0001193125-20-295997.txt   816079

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clvs-20201117.xsd EX-101.SCH 3088
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20201117_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20201117_pre.xml EX-101.PRE 11420
6 EXTRACTED XBRL INSTANCE DOCUMENT d88033d8k_htm.xml XML 3406
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 201321211
SIC: 2834 Pharmaceutical Preparations